Macquarie Group LTD Catalyst Pharmaceuticals, Inc. Transaction History

Macquarie Group LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.06 - $15.52 $14,197 - $31,210	-2,011 Reduced 1.06%	186,900 $2.42 Million
Q1 2022 May 16, 2022	SELL	$5.31 - $8.31 $3,185 - $4,986	-600 Reduced 0.32%	188,911 $1.57 Million
Q4 2021 Feb 11, 2022	SELL	$5.21 - $7.45 $122,408 - $175,037	-23,495 Reduced 11.03%	189,511 $1.28 Million
Q3 2021 Nov 12, 2021	BUY	$4.85 - $6.04 $10,670 - $13,288	2,200 Added 1.04%	213,006 $1.13 Million
Q2 2021 Aug 13, 2021	BUY	$4.29 - $6.05 $365,576 - $515,556	85,216 Added 67.85%	210,806 $1.21 Million
Q1 2021 May 14, 2021	SELL	$3.45 - $4.69 $31,867 - $43,321	-9,237 Reduced 6.85%	125,590 $579,000
Q3 2020 Nov 13, 2020	BUY	$2.97 - $5.08 $332,856 - $569,330	112,073 Added 492.54%	134,827 $401,000
Q2 2020 Aug 11, 2020	BUY	$3.48 - $5.05 $79,183 - $114,907	22,754 New	22,754 $105,000
Q1 2018 May 11, 2018	SELL	$2.39 - $4.01 $5,019 - $8,421	-2,100 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$2.51 - $4.4 $5,271 - $9,240	2,100	2,100 $8,000

326

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.